In vivo application of recombinant interleukin 2 in the immunotherapy of established cytomegalovirus infection

Reddehase, Matthias J.; Mutter, Wolfgang and Koszinowski, Ulrich H. (1987): In vivo application of recombinant interleukin 2 in the immunotherapy of established cytomegalovirus infection. In: The journal of experimental medicine, Vol. 165: pp. 650-656

Abstract

We have shown in a murine model system for cytomegalovirus (CMV) disease in the immunocompromised host that in vivo application of recombinant human IL-2 (rhIL-2) can enhance the antiviral effect of a limited number of CD8+T lymphocytes, not only in prophylaxis, but also in therapy, when virus has already colonized host tissues. The observed net effect of IL-2 was consistent with the assumption of daily effector population doublings. The prospects for IL-2-supported immunotherapy of established CMV infection depend upon the tissues involved in disease. It appears that the prospects for controlling established CMV adrenalitis are less promising than for a therapy of interstitial CMV pneumonia.

• Item Type: Journal article
• Faculties: Medicine
• Subjects: 600 Technology > 610 Medicine and health